Join Gibson Dunn lawyers for the first recorded session of a three-part series following a single life sciences collaboration and licensing dispute across its full lifecycle to explore how contract language, forum selection, and science shape leverage, timing, proof, and outcomes.
Our partners share insights on the trends shaping dealmaking in the Life Sciences sector—and what to watch in the months ahead. September 2026 · Life Sciences Featuring insights from Ryan Murr, Sebastian Fain, and Branden Berns. DEAL ACTIVITY What’s driving deal activity in the sector right now? Murr: Life Sciences deal volume is up substantially,…
Corp Fin leadership has signaled that staff time may be better spent listening to earnings calls than reviewing routine shelf filings, and a recent comment letter exchange shows why. For life sciences companies, whose calls routinely cover program-level spend, clinical data, and cash runway, inconsistencies between the call and the filings are a potential source of staff comments.
In the first six months of 2026, acquirers announced 13 qualifying acquisitions of public biopharma targets worth $66.6 billion in upfront consideration. This survey examines that period and the surge within it: what is driving it, how the deals are structured, and what it means for the parties negotiating the next one. Focusing on the…
Contingent value rights have become a defining feature of biopharma M&A, appearing in under 10% of mid-cap public-target deals before 2019 but a quarter to a third of them in every year since 2023. They let a buyer pay less cash at signing while preserving upside for selling stockholders on a binary clinical, regulatory, or…
On August 3, 2026, the California Supreme Court held in Gilead Tenofovir Cases (Aug. 3, 2026, S283862) ___ Cal.5th ___ (slip opn.), that a drug manufacturer owes no duty of care to users of a non-defective drug when deciding whether and when to commercialize an allegedly safer alternative drug. The Court reached that conclusion on…
This update summarizes noteworthy enforcement activity from the first six months of 2026. We discuss significant federal policy and state legislative developments, including the current status of state false claims statutes. We also analyze the most consequential court decisions of the first half of the year.
